2025’s Biggest Shift in Orphan Drugs: Months-Not-Years Access to Greater China
For years, everyone assumed China access meant the long road—new trials, millions in spend, and 3–5 years to national approval. [...]
Named Patient Program Overview for China
China has embraced deregulation in recent years to enable quicker approvals and access for imported treatments Guangdong–Hong Kong–Macao Greater Bay
Deflazacort Launch in China via Macau Fast-Track Pathway
Macau Fast-Track Regulatory Pathway into Mainland China Deflazacort (known as Emflaza in the U.S.) was introduced to China through an